Inhibition of KLF5 SEs using BRD4 and CDK7 inhibitors significantly downregulated KLF5 expression, suggesting an effective therapeutic strategy for treating BLBC by targeting KLF5 and its SEs.[36] These results highlight not only the role of SEs in KLF5 expression but also the pivotal role of KLF5 in establishing SE‐regulated circuits with other core regulatory factors in several cancers. The gene discussed is BRD4; the disease is cancer.